Company: IONQ
Filing Date: 2025-07-07
Form Type: 424B5
Source: 0001193125-25-155889
Chunk: 7

Company: IonQ, Inc.
Filing Date: 2025-07-07
Form: 424B5
Chunk 7
---
 net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively
could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.

Any purchaser in this offering will experience immediate and substantial dilution in the net tangible book value of shares purchased in this offering.

Since the offering price per share in this offering is substantially higher than the net tangible book value per share of our
common stock outstanding prior to this offering, any purchaser in this offering will suffer substantial dilution in the net tangible book value of shares purchased in this offering. Based on the public offering price of $55.49 per share for
aggregate net proceeds of $978.5 million, after deducting underwriting discounts and estimated offering expenses payable by us (but excluding shares issued and any proceeds received upon exercise of the Warrants), the purchasers will experience
immediate dilution of $48.96 per share, representing the difference between our as adjusted net tangible book value per share as of March 31, 2025, after giving effect to this offering and the public offering price. The exercise of outstanding
stock options, the vesting of outstanding restricted stock units and the exercise of warrants would result in further dilution of such investment. See the section titled “Dilution” below for a more detailed illustration of the dilution you
would incur if you participate in this offering.

Future sales or issuances of our common stock in the public markets, including sales by our directors and officers, or the perception of such sales, could depress the trading price of our common stock.

The sale of a
substantial number of shares of our common stock or other equity-related securities in the public markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital
through the sale of additional equity securities. We may sell large quantities of our common stock at any time pursuant to this prospectus supplement or in one or more separate offerings. In

S-5

addition, subject to the 60-day lock-up agreements that they have entered into with the underwriter (subject to
certain exceptions) and securities law restrictions, our directors and officers may sell shares of common stock at any time. We cannot predict the effect that future sales of our common stock or other equity